Read below for travel health advice on diseases and special needs from the MDtravelhealth channel.
Meningococcal meningitis is a life-threatening infection of the fluid and tissues surrounding the brain, caused by a bacterium known as Neisseria meningitides. The infection is spread person-to-person by exposure to secretions from the nose or throat. In most countries, meningococcal meningitis occurs sporadically, with small outbreaks occurring in closed communities, such as dormitories or military barracks. However, certain countries in sub-Saharan Africa, known as the "meningitis belt," periodically experience major epidemics, especially in the dry season (December through June).
The incubation period ranges from two to ten days. Most people who are infected show no symptoms, but some develop meningitis, marked by the abrupt onset of fever, headache, stiff neck, and lethargy, frequently with a rash. Meningococcal meningitis must be promptly treated with intravenous antibiotics, usually penicillin, ampicillin, or ceftriaxone. The fatality rate may approach 10%, despite appropriate therapy. Among survivors, long-term complications may include deafness, seizures, or mental impairment.
Meningococcal meningitis is rare among travelers. Meningococcal vaccine is recommended chiefly for travel to countries in the African "meningitis belt" during the dry season (December through June), especially if prolonged contact with the local populace is likely. In addition, the vaccine is periodically recommended for other countries reporting meningitis outbreaks. Immunization is required for travel to Mecca during the Hajj.
Meningococcal vaccine consists of purified polysaccharides from the bacterial capsule, rather than live or killed bacteria. The main side-effect is mild redness at the injection site. Fever is uncommon. Serious reactions are not reported. Protective antibodies develop 10-14 days after vaccination.
There are two meningococcal vaccines currently licensed in the United States. A new quadrivalent conjugate vaccine called Menactra; Sanofi-Pasteur appears to provide longer-lasting protection than an older vaccine, called (Menomune - A/C/Y/W-135; Aventis Pasteur Inc.). Both vaccines confer protection against four groups of Neisseria meningitides (A, C, Y, and W-135) but not group B, which may also cause epidemics. If at continued risk, children previously vaccinated at ages 2 through 6 years should receive an additional dose of Menactra three years after their previous meningococcal vaccine and every five years thereafter. Persons previously vaccinated at ages 7 through 55 years should receive an additional dose of Menactra five years after their previous dose and every five years thereafter, if at continued risk.
In countries other than the United States, polysaccharide vaccines limited to groups A and C (bivalent) are also available. Since an increase in the number of meningococcal infections caused by group W-135 has recently been reported (see World Health Organization), bivalent vaccines should not in general be used for international travel. A protein-polysaccharide conjugate vaccine against group C meningococci has recently become available in Canada and the United Kingdom. Unlike the older polysaccharide vaccines, the conjugate vaccine is effective in infants and young children. However, since most outbreaks in developing nations are caused by meningococci belonging to groups other than C, this vaccine is generally not adequate for international travel.
Regardless of immunization status, anyone who potentially has had direct contact with the oral or nasal secretions of an infected person should be treated prophylactically with rifampin 600 mg twice daily for 48 hours, a single 500 mg dose of ciprofloxacin, or a single 250 mg intramuscular dose of ceftriaxone. Those treated should include household contacts and anyone who sat next to an infected person during an extended plane flight.
Menomune is available in 10-dose and single-dose vials. The manufacturer recently received FDA approval to extend the use of the 10-dose vial, after reconstitution, from 10 to 35 days.
From the World Health Organization (WHO)
From the Centers for Disease Control (CDC
From Immunization Action Coalition
The MDtravelhealth channel is a source of travel health information for travellers, written by medical professionals.
The MDtravelhealth channel relies on medical professionals from all over the world to maintain the Travel Health Information on these pages.
Topic Tags are what bind the Red Planet Travel site together, and are very important.
This place has been tagged:
Before you apply read about the Medical Professionals Roles on Red Planet TravelYou need to be logged in and have applied to MDth channel to contribute to this page.
We are looking to grow the information on this site, if you have something to contribute to any page then we'd like to hear from you.
What's more you can now earn money (paid direct via Paypal) for writing descriptions about places you know.
You will need to tell other members about yourself and your relevant knowledge and experience about what you want to contribute about.
Look below for some example page types, and types of people whose views on a place might be useful to know.
Page Type: Hotel
Tell us your job, knowledge, experience..
My Experience: Doctor
If you are the owner/manager of any place, then you can, of course, take control of your page and add relevant information other visitors might want to know